Mounjaro is licensed for type 2 diabetes mellitus, whilst Zepbound is licensed for chronic weight management in adults with obesity or overweight with weight-related comorbidities
Discussion This study provides a comprehensive view of how a major formulary change influenced both treatment switching patterns and overall prescribing rates for both AOM tirzepatide and AOM semaglutide
Our blog explores this in detail: Can Weight Loss Really Lower Your Blood Pressure
A review of real world use indicates that this side effect appears to be short lived and does not last long after treatment begins
What Are Semaglutide and Tirzepatide
declares having received research grants through his affiliation from Novo Nordisk and Pharmaserve Lilly, and consulting honoraria from Pharmaserve Lilly, Sanofi-Aventis, Novo Nordisk, MSD, AstraZeneca, ELPEN Pharma, Boehringer Ingelheim, Galenica Pharma, Epsilon Health and WinMedica